Podcasts about Novo

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

A quinta temporada de Casamento às Cegas rendeu tanto que tá entretendo a gente até no pós com dezenas de polêmicas envolvendo os participantes. Mas não só de reality vive o casal que agora tem um novo hiperfoco.

EU-plan for hurtigst muligt at lukke hullerne i forsvaret. Pandoras nye topchef skal løfte Pandoras arv. Novos sparerunde får betydning for samarbejdspartnere. Dollarens dominans. Obton fortsætter solcel­le­rejsen. Nedlukning i USA. Den grønne kapita­lisme virker ikke.   Vært: Trine Duvander (trine.duvander@borsen.dk)

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for specific operations to optimizing the entire production process. Additionally, Crystalys, backed by Novo, has debuted with $205 million to tackle gout with its drug dotinurad. The FDA recently singled out Aurinia Pharmaceuticals in a LinkedIn post about surrogate endpoints for lupus nephritis drugs, criticizing companies for not conducting post-approval studies to demonstrate benefits on hard clinical endpoints. Larimar's Friedreich's ataxia drug has faced concerns about anaphylaxis, causing shares to fall. GSK's CEO Emma Walmsley has stepped down after 9 years, resealing pharma's glass ceiling. Upcoming webinars will focus on topics such as mRNA medicine and biopharma in an age of deregulation.

Peça traz personagens icônicos de Anton Tchekhov no texto do dramaturgo irlandês Brian Friel, e está em cartaz em São Paulo

Fala meus ouvintes! No ep de hoje é sobre uma mudança pra 2026! Calendário do futebol brasileiro. Ouçam!

Neste episódio, Rui Machado apresenta o novo Fundo IMGA Crescimento PPR/OICVM, destacando as suas características e diferenças face aos restantes IMGA PPRs. São ainda abordados o processo de subscrição e os principais benefícios associados a esta solução de poupança.

Os Estados Unidos entraram esta madrugada em shutdown, após o fracasso das negociações entre democratas e republicanos para aprovar o orçamento federal. Que impacto terá esta paralisação?See omnystudio.com/listener for privacy information.

Synopsis: When biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship Pioneering, and Uli Stilz, Vice President, R&D External Innovation Partners at Novo Nordisk, to explore the power of co-creation. Together, they unpack how Flagship's pioneering medicines model and Novo's Bio Innovation Hub intersect to accelerate breakthroughs in obesity, diabetes, and cardiometabolic diseases. They share lessons on building trust, navigating crises, and structuring alliances that go beyond transactions into enduring innovation ecosystems. From human disease atlases to new frameworks for agile collaboration, this episode offers a rare behind-the-scenes look at how pharma and biotech can partner differently—turning complexity into transformative therapies. Biography: Paul Biondi is a Managing Partner at Flagship Pioneering, leading Flagship's product and partnering capabilities, including Pioneering Medicines, Partnering, and Pipeline and Product Innovation. In this role, Paul oversees Pioneering Medicines, Flagship's in-house drug discovery and development unit, as well as therapeutic partnering and business development efforts for the Flagship ecosystem, including driving broad institution-wide Innovation Supply Chain partnerships with biopharma companies to jointly conceive and create innovative products. Paul also works with Flagship company CEOs and their teams to achieve the best attainable value for each company, guiding them in their pipeline strategy, product concepts, R&D execution, and partnering approach. He serves on the boards of Flagship-founded companies, including Tessera Technologies (NASDAQ: TSRA) and Valo Health. Paul Biondi is Managing Partner at Flagship Pioneering, joining after 17 years at Bristol-Myers Squibb (BMS), where he served as SVP of Strategy & Business Development and held leadership roles in R&D. He previously spent nine years at Mercer Management Consulting. Paul earned his MBA from the Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College. Uli Stilz is Corporate Vice President, R&D External Innovation Partners, External & Exploratory Innovation (E2I) at Novo Nordisk., based in Boston. He leads a global R&D team that builds creative partnerships with biotech, venture capital, academia, and research hospitals to co-create next-generation therapeutics in cardiometabolic and rare diseases. Building on the success of the Novo Nordisk Bio Innovation Hub, Uli and the E2I team drive an externally anchored portfolio of collaborations that stimulate global innovation ecosystems and advance Novo Nordisk's pipeline. Uli Stilz earned his Master's in Organic Chemistry from ETH Zürich and a Ph.D. in Biochemistry from the Max-Planck-Institute of Biochemistry in Martinsried, followed by postdoctoral research at Caltech. He began his industry career at Hoechst AG and later Sanofi, where he became Associate VP of the Innovation Unit in the Diabetes Division. Over two decades, he contributed to more than 60 preclinical and clinical drug candidates in cardiometabolic, immunology, and oncology. From 2012–2014, he served as President of the European Federation for Medicinal Chemistry. In 2014, Uli joined Novo Nordisk in Copenhagen and in 2019 moved to Boston to establish and lead the Bio Innovation Hub, now the External & Exploratory Innovation (E2I) organization. He also serves as Adjunct Professor at the University of Frankfurt, sits on editorial and scientific advisory boards, and holds board roles at the Kendall Square Association and Gensaic, while advising the aMoon Fund.

Bom dia 247_ governo Lula bate novo recorde de empregos _30_9_25_ by TV 247

Genmab køber hollandsk biotek­sel­skab for 51 mia. kr. Søstrene Grene slår rekord og øger milliardsalg med 31 pct. Novo Nordisk tilbyder ansatte degradering eller fyring. Obton stemmer ja til redningsplan. Konsor­tium køber Electronic Arts for over 50 mia. dollar. Netanyahu godkender Trumps 20-punkts fredsplan for Gaza. Vance advarer om at USA styrer mod regeringsnedlukning. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)  

Comunidade Presbiteriana Chácara Primavera contemporânea • acolhedora • transformadora Nos envie sua dúvida: http://chacara.org/talk http://chacara.org https://facebook.com/chacaraprimavera/ https://instagram.com/chacaraprimavera/

Petróleo tem novo dia de queda e Petrobras cai 1,50%. Quer saber tudo que aconteceu no mercado financeiro, nacional e internacional? Acompanhe o nosso Fechamento de Mercado e confira com quais as ações que mais mexeram com a B3, movimentação do câmbio e dos juros e muito mais! O Fechamento de Mercado da Genial é transmitido de segunda a sexta, às 17h30. Ative as notificações do programa e acompanhe ao vivo!

Depois de muita especulação, a Sony finalmente lançou um trailer de gameplay de Wolverine! Último anúncio do State of Play de setembro, o jogo da Insomniac mostrou o herói brutal, com sequências extremamente violentas, como os fãs estavam esperando. Do outro lado, tivemos também novo trailer de OD Knock, da Kojima Productions para Xbox e o visual impressiona demais. Tem também Xbox na Tokyo Game Show, novidades de GTA e muito mais!

Já em Cândido Mota/SP, seca inviabiliza semeadura com produtores avançando apenas nas áreas irrigadas

Atividades devem se estender até meados de outubro

O post Novo presidente do STF prega separação dos Poderes e despolitização de pautas que dividem o país apareceu primeiro em Conteúdo Brasil 2025.

Košarkarji Olimpije so v novo sezono vstopili z zmago v domačem superpokalnem tekmovanju, z jutrišnjim dnem pa se bo za slovenske prvake začela še evropska sezona. Zmaji bodo nastope v tej začeli pred domačim občinstvom, v uvodnem krogu evropskega pokala bo njihova nasprotnica v Stožicah španska Manresa. V Cagliariju pa se je začelo svetovno prvenstvo za jadralce v razredu formula kite. V Italiji bosta nastopila Marina in Toni Vodišek, ki se po uspešnem okrevanju po poškodbi kolena vrača v tekmovalne vode.

Do passado ao novo: a transformação da família em Cristo - Walisson e Marcela Barros by Verbo da Vida Sede

O post Novo presidente do STF prega separação dos Poderes e despolitização de pautas que dividem o país apareceu primeiro em Conteúdo Brasil 2025.

Še nekateri vsebinski poudarki oddaje: - Zapletlo se je pri sofinanciranju celovite ureditve Centra za usposabljanje Strunjan. Izolski del bo prevzela občina Piran. - Novo krožno križišče Prelésje na državni cesti med Trebnjim in Sevnico naj bi povečalo prometno varnost in pretočnost. - V Gornji Radgoni namestili nove oznake visokih vodá, ki obveščajo o poplavni ogroženosti. - Staro železarno na Ravnah na Koroškem preuredili v muzej.

Košarkarji Olimpije so v novo sezono vstopili z zmago v domačem superpokalnem tekmovanju, z jutrišnjim dnem pa se bo za slovenske prvake začela še evropska sezona. Zmaji bodo nastope v tej začeli pred domačim občinstvom, v uvodnem krogu evropskega pokala bo njihova nasprotnica v Stožicah španska Manresa. V Cagliariju pa se je začelo svetovno prvenstvo za jadralce v razredu formula kite. V Italiji bosta nastopila Marina in Toni Vodišek, ki se po uspešnem okrevanju po poškodbi kolena vrača v tekmovalne vode.

O presidente da Câmara, deputado Hugo Motta, do Republicanos da PB, pautou a urgência de oito projetos ligados à segurança pública. Entre eles estão o que aumenta as penas para homicídios de policiais e dos assaltos no novo cangaço, que passarão a ser hediondos. Se aprovado, este último crime terá pena entre 12 e trinta anos, além de não ser passível de anistia, graça ou indulto.

O Filipe foi ali e já volta, a Intel teve uma ideia, e o Scratchgate é real.

O Filipe foi ali e já volta, a Intel teve uma ideia, e o Scratchgate é real.

Comunidade Presbiteriana Chácara Primavera contemporânea • criativa • acolhedora • transformadora http://chacara.org https://facebook.com/chacaraprimavera/ https://instagram.com/chacaraprimavera/

Novo izvješće Udruge medicinskih sestara, tehničara i primalja Novog Južnog Walesa otkriva alarmantne razine rasizma i diskriminacije kojima su izloženi pripadnici autohtonih naroda i zdravstveni djelatnici iz kulturno i jezično raznolikih sredina. Sindikat je pozvao na hitnu akciju kako bi se ovaj problem riješio, budući da gotovo 70 posto ispitanika u anketi navodi da se suočavaju s rasizmom na radnom mjestu.

"Não há nada!" Nem ciclos de cinema, nem teatro. Momentos musicais, nem vê-los. E é por isso que há que fazer "um auditório à boa maneira romana". "Vamos lá desenvolver!"See omnystudio.com/listener for privacy information.

Confira os destaques do Jornal da Manhã deste sábado (27): O assessor especial da Presidência, Celso Amorim, declarou em entrevista ao UOL que os “Estados Unidos não enganam o presidente Lula (PT)”. A fala foi uma resposta às especulações sobre uma suposta “emboscada” diplomática de Donald Trump, após o encontro entre os dois líderes na ONU e comentários sobre uma boa “química”. O coordenador do Centro de Negócios Globais da FGV, Lucas Ferraz, analisou o recente aceno diplomático entre Donald Trump e Lula (PT). Ele avaliou se o gesto pode renovar o otimismo do mercado e abrir caminho para uma possível isenção das tarifas impostas ao Brasil. O economista Emmanoel Schmidt Rondon, ex-funcionário do Banco do Brasil, tomou posse nesta sexta-feira (26) como novo presidente dos Correios. Indicado por Lula (PT), ele substitui Fabiano Silva e assume a estatal em meio a uma grave crise financeira, após prejuízo de R$ 4,3 bilhões registrado no primeiro semestre de 2025. Reportagem: Igor Damasceno. Essas e outras notícias você acompanha no Jornal da Manhã. Learn more about your ad choices. Visit megaphone.fm/adchoices

O post O QUE É A ALMA apareceu primeiro em Rede Novo Tempo de Comunicação.

O Andrews conheceu a Katia e os dois viveram um grande amor, mas quando sua ex Lara apareceu, eles tiveram um caso. Um dia, ele terminou com a amante e pediu a Katia em casamento, mas de novo, teve uma recaída com a Lara. Cansado de se esconder, ele contou tudo para a esposa, que o perdoou, mas resolveu pagar na mesma moeda, traindo. Até que, a Katia ficou grávida, mas o filho era do amante. Depois de tantas loucuras, Andrews repensou a sua vida, colocou a cabeça no lugar e resolveu recomeçar com a Laís. Ele contou toda a verdade do seu passado e hoje, celebra a sua união e aprendizado com os erros do passado.

Københavns Lufthavn, Aalborg og Syd- og Sønderjylland var lukket pga. droner i luftrummet. En aggressiv opkøbsstrategi fra kapitalfond. Kommende vægttabspiller kommer sandsynligvis ikke fra Novo. Ørsteds kabler i Trumps søgelys. Nedadgående forventninger til grønne investeringer. Hård kritik af nyt affaldssystem. Den amerikanske centralbanks uafhængighed.   Vært: Trine Duvander (trine.duvander@borsen.dk)

Em meio às festividades do ano novo judaico vemos um país isolado internacionalmente e se destruindo internamente, com o esfacelamento de suas instituições.Bloco 1- Avanço do exército para a conquista e ocupação de Gaza continua deixando um rastro de mortes e destruição- Líder do Hezbollah diz que Arábia Saudita deve se juntar na luta contra Israel, o inimigo em comum.- Presidente sírio diz que está pronto para o diálogo, apesar da agressão israelense.Bloco 2- Ministra Mai Golan, investigada por corrupção, continua obstruindo a atuação da justiça.- Hanin Zoabi, ex-deputada do Balad, é presa para interrogatório depois de fala na Suíça.- Naftali Bennett diz que não permitirá o adiamento ou manipulação das próximas eleições.- Comissão Grunis não vê impedimentos na nomeação de David Zini para chefe do Shin Bet.Bloco 3- Assembléia Geral da ONU- Reconhecimento em massa da Palestina.- Repercussões em Israel.- Os discursos na ONUBloco 4- Palavra da semana- Dica cultural - Zeev Shternhell - The birth of fascist ideology : from cultural rebellion to political revolution- Correio dos ouvintesPara quem puder colaborar com o desenvolvimento do nosso projeto para podermos continuar trazendo informação de qualidade, esse é o link para a nossa campanha de financiamento coletivo. No Brasil - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠apoia.se/doladoesquerdodomuro⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠No exterior - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/doladoesquerdodomuro⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Nossa página: ladoesquerdo.comNós nas redes:bluesky - @doladoesquerdo.bsky.social e @joaokm.bsky.socialtwitter - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@doladoesquerdo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ e ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@joaokm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@doladoesquerdodomuro⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@doladoesquerdodomuro⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Tiktok - @esquerdomuroPlaylist do Spotify - Do Lado Esquerdo do Muro MusicalSite com tradução de letras de músicas - https://shirimemportugues.blogspot.com/Episódio #320 do podcast "Do Lado Esquerdo do Muro", com Marcos Gorinstein e João Miragaya.

Perfil de produção em confinamento vem mudando no Brasil com os grandes confinadores puxando crescimento

As armas nucleares continuam a representar uma das ameaças mais perigosas para a humanidade. Líderes mundiais estão revisando os graves perigos que estas armas representam e a impulsionar esforços renovados pela sua eliminação, numa reunião neste 26 de setembro, na ONU.

Recebi o Rafael Baltazar (@rbalta1) para falar sobre os problemas do Baltimore Ravens (00:00), Jaxson Dart assumindo a titularidade dos Giants (18:29) e o grande início de temporada dos Colts e Danie Jones (31:17)Apoie o podcast (20% de desconto!): ⁠⁠⁠⁠⁠https://caradossports.com.br/nfl2025/⁠⁠⁠⁠⁠Anuncie no Podcast Cara dos Sports: contato@caradossports.com.br

Novo mecanismo universal garante assento a todos os Estados-membros e promete transformar princípios em prática, colocando a humanidade no centro do avanço tecnológico; resolução sobre tema foi adotada em agosto.

Fortsat stor usikkerhed efter droneflyvninger. Fyrings­runden i Novo er begyndt siger fagforeninger. Investorer i Ørsted jubler. Mette Frederiksen laver lille ministerrokade. Ingen garanti for flere rentesænkninger i USA, siger Powell. Trump kritiserer FN og kalder klimaforandringer "nonsens". Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Futebol, informação, humor, opinião e corneta! Um programa de debate sobre tudo que envolve futebol de um jeito descontraído e animado. Veja muito mais no YouTube

Lula e Trump devem conversar por telefone ou videoconferência. Relatório contra PEC da Blindagem será votado hoje na CCJ do Senado. Conselho de Ética instaura processo que pode cassar Eduardo Bolsonaro. Morre Claudia Cardinale, atriz de ‘Era Uma Vez no Oeste’, aos 87 anos. Novo longa de Luca Guadagnino, ‘Depois da Caçada’ abrirá Festival do Rio. Morre Claudia Cardinale, atriz de ‘Era Uma Vez no Oeste’, aos 87 anos. E SUS passa a oferecer mamografia a mulheres a partir dos 40 anos sem sintomas. Essas e outras notícias, você escuta No Pé do Ouvido, com Yasmim Restum.See omnystudio.com/listener for privacy information.

Presidente do Brasil abre debate de líderes internacionais destacando “mundo em desordem” com crise do multilateralismo e enfraquecimento da democracia caminhando juntos; líder brasileiro disse que COP30 vai testar compromissos climáticos e apoiou criação de Conselho vinculado à Assembleia Geral.

Novo presidente do país, Daniel Chapo, acredita em papel multilateral da organização para promover paz, segurança, ação climática e diálogo; líder moçambicano lançou um processo de consultas nacionais em todos os cantos do país para ouvir a população após eleições polarizadas; olhando para o futuro, ele investe na juventude e na língua portuguesa.

Novo and Philip (philipchurch.com) discuss the career of producer, musician, and songwriter Butch Vig - a pivotal figure in the history of modern popular music, who's gone on to reshape the game forever - focusing on his roots, his history as a producer, including, of course, his contribution on a very special album, his time in the spotlight with his band "Garbage," auxiliary works, and how he helped blaze a trail for everything that followed. Thank you for listening.Please consider supporting us with a donation - @novodeproductions on paypal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Support our colleagues at:Philipchurch.comAlexandra-parsons.comCheck out more at www.novodeproductions.com, follow us @_novo_de, @aotb.podcast, @aotbpodcast, and if you'd like to be on the show, you can contact us at novodeproductions@gmail.com.This Episode is also brought to you by:Novel "Til the Bitter [End]emic" - Available now on Amazon. Til The Bitter [End]emic is a novel about discovery; about what we do, who we become, and what we realize is truly important when we're faced with insurmountable odds, the same kind that makes us face our own mortality.Short story - "Cancel Culture Lotto" - available now on Amazon.Zencastr - our go-to tool to record our podcast with multiple guests remotely. With Zencastr, you can record separate audio and video tracks, and it's all backed up on a secured cloud so you never lose your hard work. It's reliable, easy to use, and there's nothing to download. So go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠zencastr.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and use promo code: artofthebeholder, and get 30% off your first three months with a PRO account. So create your ⁠⁠⁠⁠⁠⁠⁠podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ today! #madeonzencastr⁠⁠⁠⁠.Note: Only the intro music is by A-CO; all other music or sound effects is stock from various outlets. Main resource for background information: wikipedia.com.

Venâncio Mondlane lança ANAMOLA, nova força política que promete renovar Moçambique. Novo ataque em Mocímboa da Praia aumenta insegurança e deslocamento de civis em Cabo Delgado. Nova lei da Comunicação Social em Moçambique é retrocesso para a liberdade de imprensa" – diz especialista.

Storbritannien, Australien, Canada og Portugal anerkender en palæstinensisk stat. Siden Doustdar er Novo-aktien steget 36 pct. Ifølge Christine Lagarde bør Danmark droppe bekymringer og bakke videre op om landets største selskab. Rekord i negative elpriser. Lundbecks missede milliardmulighed. Sprækker i det politiske blå sammenhold.   Vært: Trine Duvander (trine.duvander@borsen.dk)

Dette er episode 334 av Tid er penger.I denne episoden snakker Peter om Fed, Novo, politikk og mye annet. Alle tjenester Tid er penger leverer til lyttere kan du finne på vår nye, enkle hjemmeside: www.tiderpenger.noDer finner du:LinkedIn-sideSpotfyRSSDiscord chatBlueskyNyhetsbrevFacebook-gruppePatreonBokanbefalingerPeters CVMail Hosted on Acast. See acast.com/privacy for more information.

Novo episódio do Café Com Leite: “A Raposa e a Cegonha”. A raposa arma uma pegadinha com sopa em prato raso… e recebe uma lição elegante da cegonha. A história vira conversa sobre empatia: pensar no corpo e no jeito do outro antes de agir, ajustar “o prato” para todo mundo participar. Descubra o modo cegonha e o semáforo das emoções. Dá o play e ouça com a família! ➡️ Siga o Café Com Leite para mais episódios que divertem, ensinam e inspiram. ....................................................................................................................................................................